STOCK TITAN

Evofem Bioscienc - EVFM STOCK NEWS

Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.

Overview of Evofem Biosciences

Evofem Biosciences (symbol: EVFM) is a pioneering biotechnology company dedicated to transforming women's sexual and reproductive health with innovative, non-hormonal and on-demand solutions. As a key player in the reproductive health and innovative biotechnology space, the company develops and markets products that empower women to control their contraception through non-invasive methods, aligning with a modern lifestyle and core values.

Core Business and Product Portfolio

The cornerstone of Evofem's commercial efforts is its FDA-approved product, a hormone-free, locally-acting contraceptive vaginal gel designed for use on demand. Administered shortly before intercourse, the product works by maintaining the natural pH balance of the vaginal environment, creating conditions that are inhospitable to sperm and select pathogens. This unique mechanism not only helps reduce the risk of unintended pregnancy but also caters to women seeking alternatives to systemic, hormone-based methods.

Innovative Technology and Patent Portfolio

At the heart of Evofem Biosciences is an emphasis on innovation and proprietary technology. The company has secured multiple patents covering both the composition and methods of use for its contraceptive gel. These patents underscore the company's commitment to advancing reproductive health through scientific research and offer a foundation that supports sustained product differentiation in a competitive environment.

Market Position and Global Reach

Evofem stands out in a landscape traditionally dominated by hormonal contraceptives by offering a woman-controlled, non-systemic alternative. The company consistently addresses a fundamental need for effective contraception that aligns with personal preferences and lifestyles. Strategic partnerships with telemedicine providers and international entities have broadened its reach, providing access to diverse global markets and reinforcing its market position as a specialist in women's health innovations.

Strategic Alliances and Commercial Partnerships

The company actively forges partnerships designed to enhance product accessibility and market penetration. Collaborations with telehealth platforms cater to the increasing demand for convenient healthcare services, while agreements in key regions expand Evofem's global footprint. These business development initiatives underline the company's strategic effort to diversify revenue streams and extend its impact in addressing the unmet needs of women around the world.

Commitment to Research and Quality

Evofem Biosciences invests heavily in research and quality assurance, ensuring that its products adhere to the highest standards of safety and efficacy. Its extensive clinical research and robust regulatory filings highlight a rigorous development process that supports both patient safety and product innovation. The company's dedication to meeting stringent regulatory requirements is a testament to its commitment to advanced healthcare solutions and its credibility within the biotechnology industry.

Industry Impact and Future Context

While the company does not predict future performance, its strategic emphasis on innovative, non-hormonal contraception has already carved out a niche within the competitive landscape of women's health. Investment in technology, coupled with a diversified product strategy that now includes therapeutic agents for sexual health infections, positions Evofem as a comprehensive provider addressing multiple aspects of women's reproductive health needs. This comprehensive approach not only enhances the overall value proposition but also exemplifies the company's forward-thinking philosophy in meeting both current and emerging demands.

Conclusion

Evofem Biosciences maintains a strong, evidence-based position in the biotechnology sector, firmly rooted in its dedication to improving women's health through innovative, non-hormonal, and on-demand therapies. For investors and analysts, the company offers a complex yet coherent business model characterized by robust research, strategic partnerships, and a dynamic approach to addressing the unique needs of women across global markets.

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) announced the listing of two U.S. patents for its contraceptive product, Phexxi®, in the FDA's Orange Book. Phexxi, the first FDA-approved non-hormonal vaginal gel for contraception, was approved in May 2020. The listed patents include the '855 patent, which covers contraception methods and expires in March 2033, and the '276 patent, a composition patent expiring in March 2026. CEO Saundra Pelletier highlighted this listing as a crucial step in expanding their patent portfolio and securing the product's market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) has secured a five-year contract from the U.S. Department of Veterans Affairs to supply Phexxi®, a hormone-free contraceptive gel, starting December 15, 2020. This contract expands access to Phexxi for approximately 12 million lives, including patients in VA, Tricare, and other government health programs. The company has achieved coverage for 55% of commercial lives in the U.S., with nearly 8 million lives available at zero copay. This milestone marks a significant step in Evofem's mission to broaden access to women's reproductive health solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. A pre-recorded fireside chat featuring CEO Saundra Pelletier will be available on November 23 at 10:00 AM Eastern Time. The chat can be accessed on the company's website under the Events and Presentations section. Evofem focuses on women's sexual and reproductive health, with its product, Phexxi®, being the first hormone-free vaginal gel approved in the U.S. for pregnancy prevention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 4:00 p.m. ET. The presentation can be accessed live and archived via the Evofem website. Evofem focuses on developing innovative products for women's sexual and reproductive health, including the hormone-free contraceptive Phexxi™, and is currently evaluating EVO100 in a Phase 3 trial for preventing urogenital infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
conferences
-
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) reported financial results for Q3 2020, marking its first product sales of $0.3 million from the launch of Phexxi, a hormone-free contraceptive gel. Total operating expenses rose to $26.4 million, leading to a net loss of $29.9 million, or $(0.37) per share. The company secured a $25 million strategic investment from Adjuvant Capital to fund ongoing clinical trials and expand market access. Evofem initiated the EVOGUARD Phase 3 trial for EVO100, aimed at preventing chlamydia and gonorrhea infections in women.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
-
Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on November 9, 2020, at 5:00 p.m. ET to discuss its third quarter 2020 financial results and business highlights. Interested parties can access the live webcast and related presentation on the Company's Investor page. Dial-in numbers for participation include (866) 503-5561 (U.S. toll-free) and (253) 336-2965. A telephone replay will be available shortly after the call through November 12, 2020, using conference ID 2639368.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
conferences
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) will participate in a Virtual Investor KOL Roundtable on October 29, 2020, at 2:00 p.m. ET. CEO Saundra Pelletier and CMO Kelly Culwell will discuss women's reproductive health alongside expert Patricia Cason, RN, MS, FNP-BC. The event will delve into the current birth control landscape and contraceptive counseling. A live webcast will be available, with a replay accessible for three months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
-
Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) has commenced the pivotal Phase 3 EVOGUARD trial, enrolling its first patient to assess the efficacy and safety of EVO100 in preventing urogenital chlamydia and gonorrhea in women. With rising infection rates and increasing antibiotic resistance, the need for preventive measures like EVO100 has become critical. The trial will involve 1,730 women at risk of these infections. The FDA has granted EVO100 Fast Track Designation for chlamydia prevention, and it has also received Qualified Infectious Disease Product designation for gonorrhea.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
-
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) has secured $25 million from the sale of unsecured convertible promissory notes to Adjuvant Capital. The notes, convertible at a price of $3.65 per share, will fund the upcoming Phase 3 clinical trial, EVOGUARD, for its product EVO100 targeting urogenital chlamydia and gonorrhea prevention in women. The company aims to expand market access for its non-hormonal contraceptive, Phexxi™, approved in May 2020. This partnership aligns with Adjuvant's mission to enhance contraceptive access globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.99%
Tags
none
Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) announced new clinical trial data on Phexxi™ and EVO100 to be presented at major medical society meetings this October. The data includes insights into Phexxi users and factors affecting reinfection rates of chlamydia and gonorrhea, as well as findings related to the sexual impact of treatment. The AMPREVENCE trial enrolled 860 women, while the AMPOWER trial involved 1,384 participants, evaluating Phexxi's contraceptive efficacy. The company continues its publication strategy with nine abstracts to be presented this fall.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
none

FAQ

What is the current stock price of Evofem Bioscienc (EVFM)?

The current stock price of Evofem Bioscienc (EVFM) is $0.0094 as of April 1, 2025.

What is the market cap of Evofem Bioscienc (EVFM)?

The market cap of Evofem Bioscienc (EVFM) is approximately 832.7K.

What does Evofem Biosciences specialize in?

Evofem Biosciences specializes in developing innovative, non-hormonal, on-demand products for women’s sexual and reproductive health, primarily focusing on contraception.

How does the company's primary product work?

The company's flagship product is a locally-acting contraceptive vaginal gel that maintains the natural pH of the vagina, creating an environment that is inhospitable to sperm and certain pathogens, thereby preventing pregnancy without systemic hormones.

What makes Evofem's approach unique in the contraceptive market?

Evofem's approach is unique because it offers a woman-controlled, non-invasive, and rapidly reversible contraceptive method, unlike traditional hormone-based products, aligning with modern lifestyle preferences.

How does Evofem generate revenue?

Revenue is primarily generated through the commercialization of its FDA-approved products, strategic partnerships, licensing agreements, and maintaining a robust patent portfolio that supports product differentiation.

What role do patents play in Evofem's business model?

Patents are critical to Evofem’s business model as they protect its innovative formulations and methods, ensuring exclusivity and supporting long-term competitive advantages in the market.

How does Evofem expand its market reach?

The company expands its market reach through strategic alliances with telemedicine platforms, international commercialization agreements, and partnerships that facilitate access to diverse global markets.

How does Evofem ensure product quality and safety?

Evofem commits significant resources to research and quality assurance, adhering to extensive clinical trials and regulatory approvals to maintain high safety and efficacy standards for all its products.

What is the significance of non-hormonal contraception for women?

Non-hormonal contraception offers an alternative for women who prefer to avoid systemic hormones due to health concerns or lifestyle preferences, providing a safer and on-demand option that aligns with personal health values.
Evofem Bioscienc

Nasdaq:EVFM

EVFM Rankings

EVFM Stock Data

832.73k
113.35M
0%
0.1%
10.98%
Biotechnology
Healthcare
Link
United States
San Diego